Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.


Scientific Agenda

Saturday, August 17, 2013

7:30 am

Breakfast and registration

8:00 am

Welcome and introduction

8:05 am

Demographic survey

Session I: Updates and Reviews

8:10 am

Perspectives on pre-operative endocrine therapy

8:30 am

Genomic profiling in the adjuvant setting

8:50 am

Optimal duration of adjuvant trastuzumab

9:10 am

Emerging strategies and ongoing trials for HER2+ metastatic disease

9:30 am

Future therapeutic approaches in metastatic ER+ disease

Session II: Challenging Cases

9:45 am

Faculty panel & discussion

10:05 am

Audience questions

10:15 am

Coffee break

Session III: Teaching Lectures on Special Topics

10:35 am

Keynote: PI3K-mTOR signaling and therapeutic development for breast cancer

How I Manage…

11:00 am

Sequencing of anti-HER2 agents in the metastatic setting

11:30 am

Disease relapse on nonsteroidal aromatase inhibitors

11:45 am

Difficult-to-treat/rarer cancers (lobular carcinoma, leptomeningeal disease, etc.)

12:00 pm


1:00 pm

Keynote: Triple-negative breast cancer – current status of management and ongoing trials

Session IV: Challenging Cases

1:25 pm

Faculty panel & discussion

1:50 pm

Audience questions

2:00 pm

Coffee break

Session V: Great Debates on Breast Cancer Controversies

2:20 pm

Among those patients with high-risk ER+ disease, who should receive chemotherapy? – All patients vs. Some patients

2:50 pm

Should genetic profiling be routinely used in node-positive disease? – Yes vs. No

3:20 pm

What is the optimal neoadjuvant therapy for ER+ low-grade cancers? – Chemotherapy vs. Hormone therapy

3:50 pm

Should adjuvant hormone therapy be extended in luminal B cancers? – Yes vs. No

4:20 pm

Closing remarks and adjourn